Drug Profile
Leucine/metformin
Alternative Names: L-leucine/metformin; Metformin/L-leucine; Metformin/leucine; NS-0100Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator NuSirt Biopharma
- Class Antihyperglycaemics; Biguanides; Branched-chain amino acids; Essential amino acids; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sirtuin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
Most Recent Events
- 23 Mar 2017 Phase-II development for Type-2 diabetes mellitus is ongoing in USA (PO)
- 26 Jan 2016 NuSirt Biopharma completes a phase IIa trial in Type-2 diabetes mellitus in USA , (NCT02151461)
- 25 Jun 2015 Pharmacodynamics data from preclinical studies in Type-2 diabetes mellitus released by NuSirt Biopharma